- Home
- ANSC vs ALLO Comparison
ANSC vs ALLO Comparison
Compare ANSC & ALLO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | ANSC | ALLO |
|---|---|---|
| Founded | 2021 | 2017 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 467.0M | 539.4M |
| IPO Year | N/A | 2018 |
Fundamental Metrics
Financial Performance| Metric | ANSC | ALLO |
|---|---|---|
| Price | $11.25 | $2.27 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 12 |
| Target Price | N/A | ★ $8.36 |
| AVG Volume (30 Days) | 16.3K | ★ 4.4M |
| Earning Date | 01-01-0001 | 06-15-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 34.09 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | $141,204.81 |
| P/E Ratio | $55.07 | ★ N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $10.57 | $0.86 |
| 52 Week High | $11.27 | $2.80 |
Technical Indicators
Market Signals| Indicator | ANSC | ALLO |
|---|---|---|
| Relative Strength Index (RSI) | 56.67 | 50.79 |
| Support Level | $11.13 | $2.20 |
| Resistance Level | N/A | $2.80 |
| Average True Range (ATR) | 0.02 | 0.18 |
| MACD | 0.00 | -0.05 |
| Stochastic Oscillator | 75.00 | 16.67 |
Price Performance
Historical ComparisonAbout ANSC Agriculture & Natural Solutions Acquisition Corporation
Agriculture & Natural Solutions Acquisition Corp is a blank check company.
About ALLO Allogene Therapeutics Inc.
Allogene Therapeutics Inc is a clinical-stage biotech firm specializing in immuno-oncology, focusing on the development of genetically engineered allogeneic T-cell products for cancer and autoimmune diseases. Their pipeline includes off-the-shelf T-cell candidates designed to target cancer cells or autoreactive cells in autoimmune disorders. Notably, their allogeneic approach, derived from healthy donors, allows for broader patient eligibility and scalability. With a vision to redefine CAR T therapy, the company concentrates on core programs targeting lymphoma, leukemia, autoimmune diseases, and solid tumors. Revenue, generated from collaborations and licensing agreements, supports their research and development efforts.